X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
acute myelogenous leukemia (1) 1
adult (1) 1
age factors (1) 1
aml (1) 1
antibiotics, antineoplastic - therapeutic use (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
bone marrow (1) 1
bone-marrow (1) 1
cancer (1) 1
chemotherapy (1) 1
chemotherapy, adjuvant (1) 1
classification (1) 1
clinical trials (1) 1
combination (1) 1
cytarabine (1) 1
cytarabine - therapeutic use (1) 1
daunorubicin - therapeutic use (1) 1
disease progression (1) 1
disease-free survival (1) 1
double-blind method (1) 1
elderly-patients (1) 1
female (1) 1
flt3 mutations (1) 1
germany (1) 1
hematology, oncology and palliative medicine (1) 1
hematopoietic stem cell transplantation (1) 1
humans (1) 1
hypertension (1) 1
index medicus (1) 1
kaplan-meier estimate (1) 1
leukemia (1) 1
leukemia, myeloid, acute - diagnosis (1) 1
leukemia, myeloid, acute - drug therapy (1) 1
leukemia, myeloid, acute - mortality (1) 1
male (1) 1
medical prognosis (1) 1
middle aged (1) 1
mortality (1) 1
neoadjuvant therapy - adverse effects (1) 1
neoadjuvant therapy - mortality (1) 1
niacinamide - adverse effects (1) 1
niacinamide - analogs & derivatives (1) 1
niacinamide - therapeutic use (1) 1
oncology (1) 1
phenylurea compounds - adverse effects (1) 1
phenylurea compounds - therapeutic use (1) 1
proportional hazards models (1) 1
protein kinase inhibitors - adverse effects (1) 1
protein kinase inhibitors - therapeutic use (1) 1
recurrence (1) 1
risk factors (1) 1
standards (1) 1
stem-cell transplantation (1) 1
time factors (1) 1
transplantation, homologous (1) 1
transplants & implants (1) 1
treatment outcome (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.